Primary Job Title Chief Executive Officer Primary Organization 
HDL Therapeutics
Location Vero Beach, Florida, United States Regions East Coast, Southern US Gender Male
LinkedIn View on LinkedIn
Michael Matin has served as the CEO at HDL Therapeutics, and a member of its Board of Directors since inception. Throughout his tenure at the company, Michael has led the company’s strategic and operational management. Prior to co-founding HDL Therapeutics, Michael worked for over 20 years in commercial, product development and strategic alliance
roles in the pharmaceuticals industry, with over a decade of experience in the cardiovascular field. Michael has led the development of major cardiovascular products through clinical stage development and launch. His last two cardiovascular launches reached peak sales of over $4 billion.
Michael started his life science career at Pfizer which culminated in the launch of Aricept, a treatment for Alzheimer’s disease. Aricept became a blockbuster and the most successful Alzheimer’s therapy ever launched. To-date, no other Alzheimer’s therapy has been able to match Aricept’s commercial success. Michael joined Bayer following his tenure at Pfizer. He became responsible for reviving Bayer’s portfolio of cardiovascular products. Under his leadership, Bayer’s portfolio of cardiovascular products grew to $1 billion through expanded labeling, repositioning and re-launching major brands. Michael joined Schering-Plough to lead its portfolio of cardiovascular products through clinical development into launch. He helped build a $4 billion cardiovascular franchise at Schering-Plough.
Michael received his B.S.F.S. from the School of Foreign Service at Georgetown University and his MBA from Columbia University.
